Multifaceted microglia - key players in primary brain tumour heterogeneity
Related Experiment Video
Updated: Nov 14, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Lily Keane1, Mathilde Cheray1, Klas Blomgren2,3
1Institute of Environmental Medicine, Toxicology Unit, Karolinska Institutet, Stockholm, Sweden.
Abstract:
Microglia are the resident innate immune cells of the immune-privileged CNS and, as such, represent the first line of defence against tissue injury and infection. Given their location, microglia are undoubtedly the first immune cells to encounter a developing primary brain tumour. Our knowledge of these cells is therefore important to consider in the context of such neoplasms. As the heterogeneous nature of the most aggressive primary brain tumours is thought to underlie their poor prognosis, this Review places a special emphasis on the heterogeneity of the tumour-associated microglia and macrophage populations present in primary brain tumours. Where available, specific information on microglial heterogeneity in various types and subtypes of brain tumour is included. Emerging evidence that highlights the importance of considering the heterogeneity of both the tumour and of microglial populations in providing improved treatment outcomes for patients is also discussed.
Insights
Microglia, the brain's immune cells, are crucial in primary brain tumors. Understanding their diverse roles and heterogeneity is key to improving patient treatment outcomes.
Area of Science:
- Neuroscience
- Immunology
- Oncology
Background:
- Microglia are the primary immune cells in the central nervous system (CNS).
- They act as the first responders to injury and infection within the brain.
- Microglia are strategically positioned to be the initial immune cells encountering primary brain tumors.
Purpose of the Study:
- To review the heterogeneity of microglia and macrophages associated with primary brain tumors.
- To emphasize the importance of this heterogeneity in understanding tumor progression and prognosis.
- To discuss how considering both tumor and microglial heterogeneity can improve patient treatment outcomes.
Main Methods:
- Literature review focusing on primary brain tumors and associated microglia/macrophage populations.
- Analysis of emerging evidence on microglial heterogeneity in various brain tumor types and subtypes.
- Synthesis of information regarding the impact of heterogeneity on treatment strategies.
Main Results:
- Primary brain tumors exhibit significant heterogeneity, contributing to poor prognosis.
- Tumor-associated microglia and macrophage populations are also heterogeneous.
- Specific information on microglial heterogeneity across different brain tumor types is presented.
Conclusions:
- The heterogeneity of both primary brain tumors and their associated microglia/macrophages is critical.
- Understanding this dual heterogeneity is essential for developing effective therapeutic strategies.
- Considering microglial heterogeneity offers a promising avenue for improving patient outcomes in brain oncology.
